What is the primary reason Amgen is using non-GAAP financial measures in this report?

Amgen is using non-GAAP financial measures to provide investors with a more comparable view of its operational performance. These measures exclude significant one-time items and acquisition-related costs, such as those from the Immunex acquisition and the Genentech settlement, which can obscure underlying business trends when viewed under standard GAAP reporting.

What are the key items Amgen is excluding from its GAAP results to arrive at its non-GAAP figures?

Key items excluded from GAAP results include incremental compensation to former Immunex employees, integration costs associated with the Immunex acquisition, amortization of acquired intangible assets (like ENBREL®), the financial impact of the Genentech patent litigation settlement, cost recoveries from arbitration with Johnson & Johnson, and contributions to the Amgen Foundation. The specific exclusions vary slightly between the three-month and nine-month periods.

How should investors interpret Amgen's use of these non-GAAP measures?

Investors should view these non-GAAP measures as supplementary information to the official GAAP financial results. Amgen believes they offer valuable insights into ongoing operational performance by removing the effects of specific events like acquisitions, litigation settlements, and other non-recurring charges or gains. It's crucial to analyze both GAAP and non-GAAP figures to get a complete picture of the company's financial health and operational efficiency.

Does the report provide specific financial figures for the non-GAAP adjustments?

This 8-K filing itself does not provide the specific dollar amounts for each adjustment. It announces that a press release (Exhibit 99.1) was issued on October 21, 2003, which contains the detailed financial results, including the reconciliation of GAAP to non-GAAP measures. Investors would need to refer to that press release for the precise figures.

AMGN 8-K SEC Disclosure

Summary

This 8-K filing from Amgen Inc. (AMGN), dated October 27, 2003, announces the company's financial results for the three and nine months ended September 30, 2003. A key focus of this report is Amgen's use of non-GAAP financial measures to provide investors with a more comparable view of its performance, particularly in light of significant corporate activities. The company adjusted its reported results to exclude items such as integration costs from the acquisition of Immunex, stock-based compensation related to that acquisition, the impact of a patent litigation settlement with Genentech, and other one-time expenses or recoveries. Investors are encouraged to review Amgen's provided non-GAAP figures alongside their GAAP equivalents. The company asserts that these adjustments are intended to offer clearer insights into operational performance by removing the effects of extraordinary events and post-acquisition integration expenses. These adjusted measures are used internally for budgeting and financial planning, suggesting a strategic approach to performance evaluation that separates ongoing operational trends from acquisition-related impacts and legal settlements.

Key Highlights

1Amgen reported its financial results for the three and nine months ending September 30, 2003.
2The company is utilizing non-GAAP financial measures to present results, aiming to provide greater comparability.
3Adjustments exclude costs associated with the acquisition of Immunex Corporation, including incremental compensation and integration costs.
4The Genentech litigation settlement's financial impact is excluded from non-GAAP measures.
5Costs and benefits related to arbitration with Johnson & Johnson and contributions to the Amgen Foundation are also excluded in certain periods.
6The use of non-GAAP measures is intended to offer supplemental information to GAAP results, aiding in performance comparisons across different periods.
7Amgen uses these non-GAAP measures internally for budgeting and financial planning.

AMGEN INC 8-K Report (Oct 27, 2003)

Summary

Key Highlights

Frequently Asked Questions